NRx Pharmaceuticals Inc Cash Flow Conversion Efficiency
NRx Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, NRx Pharmaceuticals Inc (NRXPW) has a cash flow conversion efficiency ratio of 0.311x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.29 Million) by net assets ($-13.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of NRx Pharmaceuticals Inc (2017–2025)
Cash flow conversion efficiency of NRx Pharmaceuticals Inc from 2017 to 2025. This chart illustrates how NRx Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NRx Pharmaceuticals Inc share price for real-time trading data and today's change.
NRx Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
NRx Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
NRx Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NRx Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see NRXPW market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Housing Development and Infrastructure Limited
NSE:HDIL
|
-0.042x |
|
VIFRANA
RO:BIOW
|
N/A |
|
Mammoth Minerals Limited
AU:M79
|
N/A |
|
Seed Capital Solutions Plc
LSE:SCSP
|
N/A |
|
CuriosityStream Inc
NASDAQ:CURIW
|
0.093x |
|
Versus Systems Inc
NASDAQ:VSSYW
|
0.007x |
|
Pathkey.ai Ltd
AU:PKY
|
2.310x |
|
Us1 Critical Minerals Limited
AU:USC
|
-1.463x |
Annual Cash Flow Conversion Efficiency for NRx Pharmaceuticals Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of NRx Pharmaceuticals Inc from 2017 to 2025. Review NRx Pharmaceuticals Inc leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-15.94 Million | $-14.11 Million | 0.885x | +93.32% |
| 2024-12-31 | $-23.22 Million | $-10.64 Million | 0.458x | -75.19% |
| 2023-12-31 | $-11.73 Million | $-21.66 Million | 1.846x | +134.40% |
| 2022-12-31 | $7.41 Million | $-39.76 Million | -5.366x | -196.10% |
| 2021-12-31 | $20.81 Million | $-37.70 Million | -1.812x | -3601.91% |
| 2020-12-31 | $-43.77 Million | $-2.27 Million | 0.052x | +292.57% |
| 2019-12-31 | $29.50 Million | $-792.73K | -0.027x | -294.90% |
| 2018-12-31 | $69.54 Million | $-473.19K | -0.007x | -248.09% |
| 2017-12-31 | $69.47 Million | $-135.81K | -0.002x | -- |
About NRx Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone… Read more